Ustekinumab or vedolizumab for refractory metastatic Crohn's disease?

Basit Öğe Kaydı
dc.contributor.authorKurt, İdris
dc.contributor.authorTezel, Hüseyin Ahmet
dc.date.accessioned2024-06-12T10:04:09Z
dc.date.available2024-06-12T10:04:09Z
dc.date.issued2024
dc.departmentTrakya Üniversitesien_US
dc.description.abstractMetastatic Crohn's disease is a rare skin manifestation of Crohn’s disease. A variety of treatment options are available for this condition. But there is a lack of clarity regarding the treatment of resistant cases. There is ongoing debate as to which agent should be selected (vedolizumab or ustekinumab) in patients that are not responding to anti-tumor necrosis factor agents. This study identifies a unique patient who has developed a disease (metastatic Crohn's disease) under treatment with vedolizumab. Following treatment with ustekinumab, the patient regressed completely. Therefore, we recommend ustekinumab primarily in metastatic Crohn's disease.en_US
dc.identifier.doi10.17941/agd.1465245
dc.identifier.endpage31en_US
dc.identifier.issn1303-6629
dc.identifier.issn2149-0600
dc.identifier.issue1en_US
dc.identifier.startpage28en_US
dc.identifier.trdizinid1232660en_US]
dc.identifier.urihttps://doi.org/10.17941/agd.1465245
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1232660
dc.identifier.urihttps://hdl.handle.net/20.500.14551/12670
dc.identifier.volume23en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofAkademik Gastroenteroloji Dergisien_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleUstekinumab or vedolizumab for refractory metastatic Crohn's disease?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu